Bayesian Model Assessment in Joint Modeling of Longitudinal and Survival Data With Applications to Cancer Clinical Trials

Journal of Computational and Graphical Statistics

Volumn 26, Issue 1, 2017, Pages 121-133

  Zhang, Danjie ^a   Chen, Ming Hui ^b   Ibrahim, Joseph G ^c   Boye, Mark E ^d   Shen, Wei ^d  

^a GILEAD SCIENCES   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c IL   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

CPO; DIC; LPML; Monte Carlo method; Patient reported outcome (PRO)

Indexed keywords

EID: 85013098571     PISSN: 10618600     EISSN: 15372715     Source Type: Journal    
DOI: 10.1080/10618600.2015.1117472     Document Type: Article

References (54)

1. Bridges, J. F. P., Mohamed, A. F., Finnern, H. W., Woehl, A., and Hauber, A. B., (2012), “Patients’ Preferences for Treatment Outcomes for Advanced Non-Small Cell Lung Cancer:A Conjoint Analysis,” Lung Cancer, 77, 224–231.
2. Brown, E. R., and Ibrahim, J. G., (2003), “Bayesian Approaches to Joint Cure Rate and Longitudinal Models With Applications to Cancer Vaccine Trials,” Biometrics, 59, 686–693.
3. Brown, E. R., Ibrahim, J. G., and De Gruttola, V., (2005), “A Flexible B-Spline Model for Multiple Longitudinal Biomarkers and Survival,” Biometrics, 61, 64–73.
4. Chen, M.-H., (1994), “Importance-Weighted Marginal Bayesian Posterior Density Estimation,” Journal of the American Statistical Association, 89, 818–824.
5. Chen, M.-H., Ibrahim, J. G., and Sinha, D., (2004), “A New Joint Model for Longitudinal and Survival Data With a Cure Fraction,” Journal of Multivariate Analysis, 91, 18–34.
6. Chen, M.-H., Shao, Q.-M., and Ibrahim, J. G., (2000), Monte Carlo Methods in Bayesian Computation, New York:Springer-Verlag.
7. Chi, Y.-Y., and Ibrahim, J. G., (2006), “Joint Models for Multivariate Longitudinal and Multivariate Survival Data,” Biometrics, 62, 432–445.
8. ——— (2007), “Bayesian Approaches to Joint Longitudinal and Survival Models Accommodating Both Zero and Nonzero Cure Fractions,” Statistica Sinica, 17, 445–462.
9. Chib, S., (1995), “Marginal Likelihood From the Gibbs Output,” Journal of the American Statistical Association, 90, 1313–1321.
10. Crowther, M. J., (2012), “STJM:Stata Module to Fit Shared Parameter Joint Models of Longitudinal and Survival Data,” available at http://econpapers.repec.org/software/bocbocode/s457502.htm/.
11. Crowther, M. J., Abrams, K. R., and Lambert, P. C., (2013), “Joint Modeling of Longitudinal and Survival Data,” The Stata Journal, 13, 165–184.
12. Draper, D., and Krnjajić, M., (2005), “Bayesian Model Specification, Technical Report, Department of Applied Mathematics and Statistics,” University of California, Santa Cruz.
13. DeGruttola, V., and Tu, X. M., (1994), “Modeling Progression of CD4-Lymphocyte Count and Its Relationship to Survival Time,” Biometrics, 50, 1003–1014.
14. DeMuro, C., Clark, M., Doward, L., Mordin, M., and Gnanasakthy, A., (2013), “Assessment of PRO Label Claims Granted by the FDA as Compared to the EMA (2006--2010),” Value in Health, 16, 1150–1155.
15. European Medicines Agency (2005), “Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products.” Available at:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf.
16. Geisser, S., and Eddy, W. F., (1979), “A Predictive Approach to Model Selection,” Journal of the American Statistical Association, 74, 153–160.
17. Gelfand, A. E., and Dey, D. K., (1994), “Bayesian Model Choice:Asymptotics and Exact Calculations,” Journal of the Royal Statistical Society, Series B, 56, 501–514.
18. Gelfand, A. E., Dey, D. K., and Chang, H., (1992), “Model Determinating Using Predictive Distributions with Implementation via Sampling-based Methods” (with discussion), in Bayesian Statistics (Vol. 4), eds. J. M. Bernado, J. O. Berger, A. P. Dawid, and A. F. M. Smith, Oxford:Oxford University Press, pp. 147–167.
19. Geweke, J., (1989), “Bayesian Inference in Econometrics Models Using Monte Carlo Integration,” Econometrica, 57, 1317–1340.
20. Hanson, T. E., Branscum, A. J., and Johnson, W. O., (2011), “Predictive Comparison of Joint Longitudinal-Survival Modeling:A Case Study Illustrating Competing Approaches” (with discussion), Lifetime Data Analysis, 17, 3–42.
21. Hatfield, L. A., Boye, M. E., and Carlin, B. P., (2011), “Joint Modeling of Multiple Longitudinal Patient-Reported Outcomes and Survival,” Journal of Biopharmaceutical Statistics, 21, 971–991.
22. Hatfield, L. A., Boye, M. E., Hackshaw, M. D., and Carlin, B. P., (2012), “Multilevel Bayesian Models for Survival Times and Longitudinal Patient-Reported Outcomes With Many Zeros,” Journal of the American Statistical Association, 107, 875–885.
23. Henderson, R., Diggle, P. J., and Dobson, A., (2000), “Joint Modelling of Longitudinal Measurements and Event Time Data,” Biostatistics, 1, 465–480.
24. Hogan, J. W., and Laird, N. M., (1997), “Mixture Models for the Joint Distribution or Repeated Measures and Event Times,” Statistics in Medicine, 16, 239–257.
25. Ibrahim, J. G., Chen, M.-H., and Sinha, D., (2001), Bayesian Survival Analysis, New York:Springer-Verlag.
26. ——— (2004), “Bayesian Methods for Joint Modeling of Longitudinal and Survival Data With Applications to Cancer Vaccine Studies,” Statistica Sinica, 14, 863–883.
27. Ibrahim, J. G., Chu, H., and Chen, L. M., (2010), “Basic Concepts and Methods for Joint Models of Longitudinal and Survival Data,” Journal of Clinical Oncology, 28, 2796–2801.
28. Klein, J. P., van Houwelingen, H. C., Ibrahim, J. G., and Scheike, T. H. (eds.), (2013), Handbook of Survival Analysis, Boca Raton, FL:Chapman & Hall.
29. Lavalley, M. P., and DeGruttola, V., (1996), “Model for Empirical Bayes Estimators of Longitudinal CD4 Counts,” Statistics in Medicine, 15, 2289–2305.
30. Law, N. J., Taylor, J. M. G., and Sandler, H., (2002), “The Joint Modeling of a Longitudinal Disease Progression Marker and the Failure Time Process in the Presence of Cure,” Biostatistics, 3, 547–563.
31. Meketon, M. S., and Schmeiser, B. W., (1984), “Overlapping Batch Means:Something for Nothing?” Proceedings of the Winter Simulation Conference, pp. 227–230.
32. Patricia, H. J., Gralla, R. J., Liepa, A. M., Symanowski, J. T., and Rusthoven, J. J., (2006), “Measuring Quality of Life in Patients With Pleural Mesothelioma Using a Modified Version of the Lung Cancer Symptom Scale (LCSS):Psychometric Properties of the LCSS-Meso,” Supportive Care in Cancer, 14, 11–21.
33. Pawitan, Y., and Self, S., (1993), “Modeling Disease Marker Processes in AIDS,” Journal of the American Statistical Association, 88, 719–726.
34. Philipson, P., Sousa, I., Diggle, P., Williamson, P., Kolamunnage-Dona, R., and Henderson, R., (2012), “joineR:Joint Modelling of Repeated Measurements and Time-to-Event Data,” R Package Version 1.0-3. Available at http://cran.r-project.org/web/packages/joineR/index.html.
35. Pinheiro, J. C., and Bates, D. M., (1995), “Approximations to the Log-Likelihood Function in the Nonlinear Mixed-Effects Model,” Journal of Computational and Graphical Statistics, 4, 12–35.
36. Proust-Lima, C., Philipps, V., Diakite, A., and Liquet, B., (2014), “lcmm:Estimation of Extended Mixed Models Using Latent Classes and Latent Processes,” R package version 1.6-4. Available at http://cran.r-project.org/web/packages/lcmm/index.html.
37. Rizopoulos, D., (2012a), Joint Models for Longitudinal and Time-to-Event Data:With Applications in R, Boca Raton, FL:CRC Press.
38. ——— (2012b), JM:Joint Modeling of Longitudinal and Survival Data. R package version 1.1-0. Available at http://rwiki.sciviews.org/doku.php?id=packages:cran:jm.
39. ——— (2014), “JMbayes:Joint Modeling of Longitudinal and Time-to-Event Data Under a Bayesian Approach,” R package version 0.5-3. Available at http://cran.r-project.org/web/packages/JMbayes/index.html.
40. Rothman, M., Burke, L., Erickson, P., Leidy, N. K., Patrick, D. L., and Petrie, C. D., (2009), “Use of Existing Patient-Reported Outcome (PRO) Instruments and Their Modification:The ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report,” Value in Health, 12, 1075–1083.
41. Schluchter, M. D., (1992), “Methods for the Analysis of Informatively Censored Longitudinal Data,” Statistics in Medicine 11, 1861–1870.
42. Siddiqui, F., Liu, A. K., Watkins-Bruner, D., and Movsas, B., (2014), “Patient-Reported Outcomes and Survivorship in Radiation Oncology:Overcoming the Cons,” Journal of Clinical Oncology, 32, 2920–2927.
43. Song, X., Davidian, M., and Tsiatis, A. A., (2002), “An Estimator for the Proportional Hazards Model With Multiple Longitudinal Covariates Measured With Error,” Biostatistics, 3, 511–528.
44. Spiegelhalter, D. J., Best, N. G., Carlin, B. P., and van der Linde, A., (2002), “Bayesian Measures of Model Complexity and Fit,” Journal of the Royal Statistical Society, Series B, 64, 583–639.
45. Thompson, J. K., Westbom, C. M., and Shukla, A., (2014), “Malignant Mesothelioma:Development to Therapy,” Journal of Cellular Biochemistry 115, 1–7.
46. Tsiatis, A. A., and Davidian, M., (2004), “Joint Modeling of Longitudinal and Time-to-Event Data:An Overview, Statistica Sinica 14, 809–834.
47. U.S. Department of Health and Human Services (2009), “Guidance for industry. Patient-reported outcome measures:use in medical product development to support labeling claims,” Available at:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
48. Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., Niyikiza, C., and Paoletti, P., (2003), “Phase III Study of Pemetrexed In Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma,” Journal of Clinical Oncology 21, 2636–2644.
49. Wang, P., Shen, W., and Boye, M. E., (2012), “Joint Modeling of Longitudinal Outcomes and Survival using Latent Growth Modeling Approach in a Mesothelioma Trial,” Health Services and Outcomes Research Methodology, 12, 182–199.
50. Xu, J., and Zeger, S. L., (2001a), “Joint Analysis of Longitudinal Data Comprising Repeated Measures and Times to Events,” Applied Statistics, 50, 375–387.
51. ——— (2001b), “The Evaluation of Multiple Surrogate Endpoints,” Biometrics 57, 81–87.
52. Zhang, D., Chen, M.-H., Ibrahim, J. G., Boye, M. E., and Shen, W., (2015), “Assessment of Fit in Longitudinal Data for Joint Models With Applications to Cancer Clinical Trials” in Applied Statistics in Biomedicine and Clinical Trials Design---Selected Papers from 2013 ICSA/ISBS Joint Statistical Meetings, eds. Z. Chen, A. Liu, Y. Qu, L. Tang, N. Ting, and Y. Tsong, New York:Springer, pp. 347–365.
53. Zhang, D., Chen, M.-H., Ibrahim, J. G., Boye, M. E., and Shen, W., (2016), “JMFit:A SAS Macro for Joint Models of Longitudinal and Survival Data,” Journal of Statistical Software, 71, 1--24. DOI:10.18637/jss.v071.i03.
54. Zhang, D., Chen, M.-H., Ibrahim, J. G., Boye, M. E., Wang, P., and Shen, W., (2014), “Assessing Model Fit in Joint Models of Longitudinal and Survival Data With Applications to Cancer Clinical Trials, Statistics in Medicine 33, 4715–4733.